What do systematic reviews say?

Avoralstat vs placebo

Avoralstat showed no clear difference in risk of HAE attacks (during compared with placebo (moderate certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 0.99 [0.92, 1.06]
  1 study · 110 participants
  Moderate

Berotralstat vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Berotralstat vs placebo or active control

Berotralstat showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 0.77 [0.02, 24.03]
  3 studies · 128 participants
  Low

Berotralstat vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 130 participants
  Moderate

Berotralstat vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 50 participants
  Low

Berotralstat vs placebo or active control

Berotralstat showed no clear difference in adverse events(during compared with placebo or active control (moderate certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 1.03 [0.88, 1.22]
  3 studies · 128 participants
  Moderate

C1 esterase inhibitor vs placebo or active control

C1 esterase inhibitor may leads to lower risk of HAE attacks (during compared with placebo or active control (low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 0.29 [0.16, 0.5]
  1 study · 43 participants
  Low

C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 45 participants
  Low

C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

C1 esterase inhibitor vs placebo or active control

It is very uncertain whether C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 0.34 [0.01, 8.14]
  1 study · 44 participants
  Very low

C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 36 participants
  Low

Avoralstat vs placebo

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 134 participants
  Low

C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

C1 esterase inhibitor vs placebo or active control

C1 esterase inhibitor showed no clear difference in adverse events (during compared with placebo or active control (moderate certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 1.03 [0.84, 1.27]
  1 study · 44 participants
  Moderate

Plasma‐derived C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Plasma‐derived C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 71 participants
  Low

Plasma‐derived C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Plasma‐derived C1 esterase inhibitor vs placebo or active control

It is very uncertain whether plasma‐derived C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 0.54 [0.09, 3.1]
  1 study · 71 participants
  Very low

Plasma‐derived C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 31 participants
  Low

Plasma‐derived C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found